RUO
In 2010, the U.S. FDA and Taiwan’s Department of Health published information on the use of Clopidogrel, requiring that generic versions of the drug include a boxed warning that the drug’s efficacy will be reduced in patients with the low metabolic activity of the liver enzyme CYP2C19, and that medical professionals should consider using other anticoagulant drugs or adjusting the dose.
